6-KThe Wire
NOVO NORDISK A S files 6-K
Filed Mar 27, 2026 · 3mo ago · Accession 0001171843-26-001959
Plain English
Novo Nordisk announced the US FDA approval of Awiqli® (insulin icodec-abae) injection, the first and only once-weekly basal insulin for adults with type 2 diabetes. The company expects to launch Awiqli® nationwide in the US in the second half of 2026.
Filing details
- Company
- NOVO NORDISK A S
- Ticker
- NVO
- CIK
- 353278
- Form type
- 6-K
- Filing date
- Mar 27, 2026
- Report date
- Mar 27, 2026
- Document
- f6k_032626.htm
- Size
- 158 KB